Supplemental material
OncoImmunology
Volume 7, 2018 - Issue 6
MIATA Compliant Research Paper
Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial
, , , , 
, , , , , , , , , , , , & show all
Ruth PlummerNorthern Institute for Cancer Research, Medical School, University of Newcastle-upon-Tyne and Wear, UKhttps://orcid.org/0000-0003-0107-1444View further author information
https://orcid.org/0000-0003-0107-1444View further author information, , , , , , , , , Lee MachadoScancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UKhttps://orcid.org/0000-0001-7974-2178View further author information
https://orcid.org/0000-0001-7974-2178View further author information, Ian DanielsScancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UKhttps://orcid.org/0000-0002-0504-9909View further author information
https://orcid.org/0000-0002-0504-9909View further author information, Mohamed GijonScancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UKhttps://orcid.org/0000-0002-2444-0727View further author information
https://orcid.org/0000-0002-2444-0727View further author information, & show allRelated Research Data
Nivolumab plus Ipilimumab in Advanced Melanoma
Source:
Massachusetts Medical Society
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
Source:
Proceedings of the National Academy of Sciences
Tailoring early-phase clinical trial design to address multiple research objectives.
Source:
Springer Science and Business Media LLC
High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment
Source:
Public Library of Science (PLoS)
Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics.
Source:
The American Association of Immunologists
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes
Source:
American Association for Cancer Research (AACR)
Electroporation for DNA immunization: clinical application.
Source:
Informa UK Limited
In Vivo Induction of a High-Avidity, High-Frequency Cytotoxic T-Lymphocyte Response Is Associated with Antiviral Protective Immunity
Source:
American Society for Microbiology
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
Source:
Rockefeller University Press
Pre-Existing Immunity to Tyrosinase-Related Protein (TRP)-2, a New TRP-2 Isoform, and the NY-ESO-1 Melanoma Antigen in a Patient with a Dramatic Response to Immunotherapy
Source:
The American Association of Immunologists
Cellular immune response
Source:
Wiley
Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration.
Source:
Informa Healthcare
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency.
Source:
American Association for Cancer Research (AACR)
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Source:
The American Association of Immunologists
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Source:
Massachusetts Medical Society
Antibodies designed as effective cancer vaccines
Source:
Informa UK Limited
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
Source:
Massachusetts Medical Society
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Source:
Springer Science and Business Media LLC
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Source:
Massachusetts Medical Society
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
Source:
MDPI AG
DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells.
Source:
Wiley
Peptide Delivery Systems for Cancer Vaccines
Source:
Wiley
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
Source:
Impact Journals, LLC
Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
Source:
Elsevier BV
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Source:
Massachusetts Medical Society
SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade
Source:
Taylor & Francis
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Source:
Springer Science and Business Media LLC
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
Source:
Rockefeller University Press
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Source:
Rockefeller University Press
Pathologic expression of MHC class II is driven by mitogen-activated protein kinases.
Source:
HAL CCSD
Linking provided by
